stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Novartis AG

Switzerland · SIX: NOVN.SW · Market cap: · P/E: · P/S:

Novartis develops and sells prescription medicines that treat serious diseases, from cancer to heart failure to rare genetic conditions.

Novartis is one of the world's largest makers of prescription drugs. It doesn't sell aspirin to shoppers or run pharmacies; it sells expensive, often life-saving medicines to hospitals, doctors, insurers, and governments, mostly in wealthy countries. When you or a family member gets a powerful cancer drug, a heart-failure pill, or an injection for a rare genetic disease, there's a decent chance it came from Novartis.

The company's biggest business is its innovative-medicine arm, which sells branded drugs protected by patents. Its best-known products treat heart failure, multiple sclerosis, skin conditions, and several cancers. It also has a large generics business called Sandoz — think of it as the discount version of the drug world, selling cheaper copies of medicines whose patents have expired. That mix matters because the two halves behave very differently: branded drugs earn fat profits while patents last, then fall off a cliff when copycats arrive; generics earn thin margins but provide steady volume. (Novartis has been spinning off Sandoz, so watch for that split.) Why do customers pay up? Because a drug that keeps a heart patient out of the hospital, or shrinks a tumor, is worth far more than its manufacturing cost. Novartis spends enormous sums on research — billions a year — hunting for the next blockbuster, and it is competing against giants like Pfizer, Merck, and Roche. The catch: drug development is a brutal lottery. Most experiments fail, patents eventually expire, and governments keep pushing to pay less for medicines. A single blockbuster losing its patent can wipe out billions in sales overnight.


Novartis is headquartered in Basel, Switzerland, a city that is essentially a global drug-making capital. The company generates huge free cash flow, which it uses to fund research, pay a hefty dividend, and buy back its own shares. It has been reshaping itself lately — spinning off its eye-care unit Alcon and moving to separate Sandoz — to focus on the high-margin branded-drug business. The bet is simple: fewer distractions, more bets on breakthrough medicines.

Saved answer · last researched 15 Nov 2026